The pharmaceutical plastic packaging market size is projected to expand from USD 14.39 billion in 2025 and USD 15.13 billion in 2026 to USD 19.41 billion by 2031, registering a CAGR of 5.11% between 2026 to 2031. This report is Segmented by Raw Material (Polypropylene, Polyethylene Terephthalate, and More), Product Type (Solid Containers, Liquid and Dropper Bottles, and More), Drug Delivery Route (Oral, Parenteral, Nasal, Pulmonary, and More), and Country (United Kingdom, Germany, France, Spain, Italy, Belgium, Sweden, Rest of Europe). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Converters face a dual challenge of validating post-consumer recycled polyethylene terephthalate that clears ISO 15378 sterility thresholds and sourcing medical-grade recycled high-density polyethylene, volumes of which remain scarce at fewer than five certified European compounders. High-density polyethylene is nonetheless gaining share in child-resistant applications where stiffness reduces torque variability. Polyvinyl-chloride-free laminates are displacing legacy blister films in Scandinavia as hospital systems ban dioxin-emitting materials. Overall, raw-material diversification is set to intensify, reinforcing competitive moats for suppliers that control resin purification and polymer science expertise within the broader pharmaceutical plastic packaging market.
Europe Pharmaceutical Plastic Packaging Market Trends and Insights
Rising Demand for Child-Resistant and Senior-Friendly Packs
Germany’s 2025 mandate requiring child-resistant packaging for prescription opioids ignited a retrofit wave across central-European filling lines, lengthening development cycles by up to 12 weeks. An aging European population exceeding 130 million individuals over 65 is simultaneously pressuring designers to lower opening torque and enhance tactile cues. Dual-certified closures now command 15%-20% price premiums that converters typically recoup within 18 months of launch. Specialty suppliers such as AptarGroup and Weener Plastics, owners of one-handed opening patents, have captured early share as pharmaceutical plastic packaging market customers migrate to ISO 8317-compliant systems. National authorities in France and Sweden are following Germany’s lead, expanding addressable volume for certified closures across Western Europe.Surge in Biologics Needing Advanced Parenteral Plastics
European Medicines Agency approvals for biologics climbed to 47 new entities in 2025, up 24% in two years, with large-molecule drugs now comprising 62% of the centralized-procedure pipeline. These sensitive formulations favor cyclic-olefin polymer and cyclic-olefin copolymer containers that exhibit vapor-transmission rates below 0.1 g m⁻² day⁻¹. West Pharmaceutical Services’ Daikyo Crystal Zenith syringe captured 28% of regional prefilled-syringe volume for high-concentration biologics after demonstrating silicon migration under 5 ppb. Contract manufacturers in Belgium and Germany have installed polymer-vial handling robots, reducing manual inspection and shortening time-to-market by up to six weeks. This biologics wave is expected to underpin the long-term upward trajectory of the pharmaceutical plastic packaging market.Volatile PP and PET Resin Prices
Spot polypropylene and polyethylene terephthalate prices fluctuated between EUR 1,050 and EUR 1,420 per ton in 2025, reflecting cracker outages and tariff shifts. Southern European converters, reliant on imports from Northern Europe, absorbed Q2 2025 spikes of 18% when BASF’s Ludwigshafen and TotalEnergies’ Antwerp facilities experienced unplanned shutdowns. Forty-two percent of pharmaceutical packaging suppliers have since moved to quarterly price-index clauses, but smaller firms still lack hedging capacity, exposing margins to 200-300 bp erosion during peaks. Persistent volatility adds near-term cost pressure across the pharmaceutical plastic packaging market.Other drivers and restraints analyzed in the detailed report include:
- EU Circular-Economy Rules Accelerating Recyclable Plastics
- E-Commerce Pharma Boosting Protective Secondary Packaging
- Stricter Extractables and Leachables Limits
Segment Analysis
Polypropylene retained the largest slice of 2025 demand at 33.44%, anchoring child-resistant caps, solid containers, and prefilled-syringe barrels. Polyethylene terephthalate followed at roughly 22%, prized for oxygen-barrier clarity in liquid bottles and blister backing. Yet the “Others” bucket, where cyclic-olefin polymers and bio-polymers reside, already contributes up to 17% of revenue and is expanding fastest. The pharmaceutical plastic packaging market size for cyclic-olefin copolymer vials is forecast to expand well above the overall growth trajectory as biologics manufacturers prize ultra-low extractables. Bio-polymer adoption is presently confined to secondary packs, but Alpla’s 2025 polylactic-acid cough-syrup bottle illustrated how renewable resins can meet 18-month shelf-life targets without sacrificing drop-impact performance.Converters face a dual challenge of validating post-consumer recycled polyethylene terephthalate that clears ISO 15378 sterility thresholds and sourcing medical-grade recycled high-density polyethylene, volumes of which remain scarce at fewer than five certified European compounders. High-density polyethylene is nonetheless gaining share in child-resistant applications where stiffness reduces torque variability. Polyvinyl-chloride-free laminates are displacing legacy blister films in Scandinavia as hospital systems ban dioxin-emitting materials. Overall, raw-material diversification is set to intensify, reinforcing competitive moats for suppliers that control resin purification and polymer science expertise within the broader pharmaceutical plastic packaging market.
Complete Report Scope:
- By Raw Material
- Polypropylene (PP)
- Polyethylene Terephthalate (PET)
- Low-Density Polyethylene (LDPE)
- High-Density Polyethylene (HDPE)
- Others, Raw Material (COP, COC, PVC-Free Blends, Bio-Polymers)
- By Product Type
- Solid Containers
- Liquid and Dropper Bottles
- Nasal Spray Bottles
- Oral-Care Packs
- Pouches / Sachets
- Vials and Ampoules (Polymer)
- Cartridges
- Prefilled Syringes
- Caps and Closures
- Others, Product Type (Unit-Dose Strips, Inhaler Canisters)
- By Drug Delivery Route
- Oral
- Parenteral
- Nasal
- Pulmonary
- Transdermal
- By Country
- United Kingdom
- Germany
- France
- Spain
- Italy
- Belgium
- Sweden
- Rest of Europe
List of Companies Covered in this Report:
- Gerresheimer AG
- Amcor PLC
- AptarGroup Inc.
- Origin Pharma Packaging
- Pretium Packaging
- Klockner Pentaplast
- Comar
- Gil Plastic Products Ltd
- Drug Plastics Group
- West Pharmaceutical Services Inc.
- Nemera
- Bormioli Pharma
- Alpla Group
- Sanner GmbH
- Tekni-Plex
- Weener Plastics
- Jabil Healthcare (Nypro)
- Stevanato Group (EZ-Fill Polymer Vials)
- Raumedic AG
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Gerresheimer AG
- Amcor PLC
- AptarGroup Inc.
- Origin Pharma Packaging
- Pretium Packaging
- Klockner Pentaplast
- Comar
- Gil Plastic Products Ltd
- Drug Plastics Group
- West Pharmaceutical Services Inc.
- Nemera
- Bormioli Pharma
- Alpla Group
- Sanner GmbH
- Tekni-Plex
- Weener Plastics
- Jabil Healthcare (Nypro)
- Stevanato Group (EZ-Fill Polymer Vials)
- Raumedic AG
